Kornimate/medical-research-clean huggingface dataset:
effect of simethicone on reducing bowel interference during tubal resection

Conditions: Sterility, Postpartum

Summary: tubal ligation is an everyday procedure for permanent female sterilization. it is usually performed after a vaginal delivery. minilaparotomy is generally performed by doing small incision at infraumbilical area. this minimal access surgery requires adequate operative field exposure. bowel interference, which obscures visualization of the operative field has been recognized as one of the major obstacles during this procedure. we found problems while doing surgery in small space and one of them is bowel interferance which obscures vision. this could lead to prolonged operation and complications. simethicone is an antifoaming agent that use in bowel preparation prior to various procedures including laparoscopy, colonoscopy, endoscopy, and open major abdominal operations. simethicone is proven to break the bubble and reduce intraluminal gas. this effect could result in reduction of bowel dilatation that interfere with the proper identification of the adnexal area. benefit of taking simethicone prior to do minilaparotomy for tubal resection has not been examined. objectives: to examine the effect of simethicone on reducing bowel interference during minilaparotomy for tubal resection. design: a randomized controlled trial in women, age 20-45 years, undergoing postpartum sterilization after vaginal delivery at faculty of medicine, chiang mai university hospital. the participants will be randomly assigned into one of two study groups: intervention (taking simethicone) and control (not taking simethicone). for the intervention group, each woman will take simethicone (80 mg) 2 tablet chewing with water 50 ml at 2-8 hours before surgery. fasting at least 6 hours before surgery. for the control group, the women will receive the same standard perioperative care without taking simethicone. the primary outcome measure will be surgeon-rated operative difficulty score, which is a visual analog scale based on assess from exposure of to the operative field in visual analog scale by surgeon. the secondary outcome will be operative time and incidence of intraoperative and postoperative complications.


Eligibility criteria:
inclusion criteria: * women requesting postpartum sterilization by minilaparotomic tubal resection after vaginal delivery at faculty of medicine, chiang mai university exclusion criteria: * pre-pregnancy bmi \> 25 kg/m2 * intraoperative general anesthesia or epidural anesthesia * previous abdominal surgery except for appendectomy * known bowel disorder including crohn's disease, ulcerative colitis, previous bowel surgery
effect of biologic therapy on surgical outcomes for perforated crohn's patients

Conditions: Crohn Disease

Summary: crohn's disease patients who present by intestinal perforation as the first presentation are hard to deal with. surgical techniques as anastmosis or diversion stoma and active course of the disease may greatly affect the quality of life. in post-operative period, is the priority to avoid the post operative complications and to improve surgical outcomes or to stop active course of the disease and to induce remission?. so, those patients were classified into two groups. one group will receive biological therapy early post operative and the other group will receive it 2 or 3 months later after surgery and the investigators will compare results between the two groups.


Eligibility criteria:
inclusion criteria: * patients at or above 18 years old * patients with perforated bowel diagnosed as crohn's disease at presentation underwent surgery exclusion criteria: * patients less than 18 years old * well known crohn's disease patients on medical treatment * associated bowel disease as malignancy and diverticulosis.

Keywords: perforation biologic therapy ileostomy
study on the impact of electroacupuncture combined with self-acupressure on the quality of life of patients with early-stage breast cancer undergoing chemotherapy

Conditions: Electroacupuncture; Quality of Life (QOL); Acupressure; Breast Cancer; Chemotherapy

Summary: this randomized controlled clinical trial aims to evaluate the effect of electroacupuncture combined with self-acupressure on the quality of life of early-stage breast cancer patients receiving chemotherapy.

this study is a parallel-group, blinded (participant, evaluator, and statisticians), randomized controlled trial to investigate the effect of electroacupuncture combined with self-acupressure on the quality of life of early-stage breast cancer patients receiving chemotherapy. patients in each group will receive electroacupuncture or sham electroacupuncture during the first week of the chemotherapy cycle. they will receive self-acupressure or sham acupressure during the second and third weeks of the chemotherapy cycle. participants will be asked to complete the eq-5d-5l and fact-b scales. primary and secondary outcomes will be assessed.

Eligibility criteria:
inclusion criteria: 1. aged 18 years or older and aged 75 years or younger, inclusive. with an eastern cooperative oncology group (ecog) performance status of 0-2; 2. patients who have not received prior chemotherapy and are scheduled to receive at least 4 cycles of adjuvant or neoadjuvant chemotherapy or combination targeted therapy; 3. normal organ function with platelets ≥ 100\*10\^9/ l, hemoglobin ≥ 90 g/l, serum creatinine ≤ 1.5 mg/dl (133 mmol/l), or creatinine clearance ≥ 60 ml/min, total bilirubin ≤ 1.5 times the upper limit of normal (uln), alanine aminotransferase ≤ 2.5 times uln, and aspartate aminotransferase ≤ 2.5 times uln; 4. premenopausal women need appropriate contraception; 5. ability to understand the study well and complete the study questionnaire. exclusion criteria: 1. patients with needle phobia or allergy to stainless steel needles; and 2. current diagnosis of mental illness (e.g., major depression, obsessive-compulsive disorder, or schizophrenia); 3. history of autoimmune diseases, blood disorders, or organ transplantation, or long-term use of hormones or immunosuppressants; 4. comorbid bleeding disorders or thyroid dysfunction; 5. implantation of a pacemaker; pregnancy or breastfeeding; 6. a plan for adjuvant radiotherapy in the upcoming chemotherapy cycle; 7. current active infection; 8. acupuncture treatment within the last four weeks; 9. patients who are allergic to the drugs used; 10. use of other traditional chinese medicine (tcm) techniques such as chinese herbs in the next chemotherapy cycle.

Keywords: electroacupuncture self-acupressure quality of life (qol) breast cancer
clinical outcomes in hereditary cancer

Conditions: Breast Cancer; Pancreatic Cancer

Summary: compare the clinical characteristics and post-surgical outcomes (overall survival)of pancreatic cancer patients of ashkenazi descent with or without germline founder mutations in brca1 or brca2 . compare the clinical characteristics and outcomes (time to progression) of breast cancer patients of ashkenazi descent with or without germline founder mutations in brca1 or brca2 receiving paclitaxel chemotherapy for metastatic disease.

compare the clinical characteristics and post-surgical outcomes (overall survival)of pancreatic cancer patients of ashkenazi descent with or without germline founder mutations in brca1 or brca2 . compare the clinical characteristics and outcomes (time to progression) of breast cancer patients of ashkenazi descent with or without germline founder mutations in brca1 or brca2 receiving paclitaxel chemotherapy for metastatic disease.

Eligibility criteria:
inclusion criteria: * included in db0363-03 * jewish religious preference at registration * archival material available for testing * adequate post-surgical follow-up * jewish religious preference at registration * archival material available for testing * adequate follow-up to determine time to progression exclusion criteria: -subjects will not be included in the analyses if a dna sample cannot be obtained.

Keywords: ashkenazi ancestry mutations in brca1 or brca2 breast cancer pancreatic cancer
defining adolescent nausea through brain imaging and neurostimulation response

Conditions: Functional Gastrointestinal Disorders

Summary: this study evaluates the efficacy of auricular neurostimulation via an non-invasive percutaneous electrical nerve field stimulator (penfs) in adolescents with functional nausea. a neurostimulator is applied to the outer ear and stimulates several nerves that are thought to be involved in transmission of nausea and vomiting signals. half of the study subjects will receive an active nerve stimulator while the other half will receive an inactive one.

by stimulating branches of several cranial nerves in the outer ear, this study aims to improve symptoms and quality of life in adolescents with functional nausea. the study has the following specific aims: 1. to define adolescent functional nausea into subtypes based on clinical characterization and physiologic testing. 2. evaluating the efficacy of auricular neurostimulation via penfs for functional nausea. subjects will be randomized into two groups: 1) neurostimulation versus 2) sham. they will receive either an active or non-active (sham group) device for 5 days each week x 4 weeks total. those who do not improve will receive an additional 4 weeks of therapy with active stimulation. 3. investigate possible brain functional connectivity changes induced by auricular neurostimulation compared to patients with irritable bowel syndrome and healthy controls

Eligibility criteria:
inclusion criteria: * meeting pediatric rome iv criteria for functional nausea * english-speaking and able to verbalize their condition and concerns about nausea, pain and other symptoms * lack of other explanation for symptoms * intact external ear that is free of infection or severe dermatological conditions, - - no currently implanted electrical device exclusion criteria: * medically complex and/or suffering from medical condition that may explain symptoms * taking a medication that may explain symptoms * significant developmental delays * patients treated with a new drug affecting the central nervous system within 4 weeks of study start * infection or severe dermatological condition of ear * currently implanted electrical device * patients with a history of severe allergy to adhesives
safety of cultured allogeneic adult umbilical cord derived mesenchymal stem cell intrathecal injection for als

Conditions: Amyotrophic Lateral Sclerosis

Summary: this trial will study the safety and efficacy of intrathecal injection of cultured allogeneic adult umbilical cord derived mesenchymal stem cells for the treatment of amyotrophic lateral sclerosis

amyotrophic lateral sclerosis is a devastating disease. there is evidence that mesenchymal stem cell treatment is safe and can improve the prognosis of afflicted patients. patients with als will receive three intrathecal injections of cultured allogeneic adult umbilical cord derived mesenchymal stem cells. the dose for each injection will be 50 million cells and the injections will be at two-month intervals. patients will be evaluated within one month pre treatment and at 1, 6, 12, 24, 36, and 48 months post treatment for safety and efficacy.

Eligibility criteria:
inclusion criteria: * diagnosis of amyotrophic lateral sclerosis. * understanding and willingness to sign a written informed consent document exclusion criteria: * active infection * active cancer * chronic multisystem organ failure * pregnancy * anticoagulation medicine use * clinically significant abnormalities on pre-treatment laboratory evaluation * medical condition that would (based on the opinion of the investigator) compromise patient's safety. * previous organ transplant * hypersensitivity to sulfur * continued drug abuse * pre-menopausal women not using contraception

Keywords: amyotrophic lateral sclerosis als stem cells
outcomes comparison of chronic immune thrombocytopenic purpura (itp) patients switched to eltrombopag and romiplostim

Conditions: Immune Thrombocytopenic Purpura

Summary: chronic immune thrombocytopenic purpura (itp) is characterized by low platelet counts and the risk of severe bleeding complications. the two recently introduced tpo-ra drugs, namely, eltrombopag and romiplostim, have shown efficacious sustained response with continuous administration. both drugs are indicated for the treatment of thrombocytopia in patients with chronic itp who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy. while these trials address important clinical questions they were not intended to evaluate what happens in the real-world settings with actual patient living daily lives. the purpose of this health outcomes study is to understand how the two tpo receptor agonists (tpo-ra) currently available in the us are being used in clinical practice and how their use impacts chronic itp patients' daily lives. the study hypothesis is that patients who switched to eltrombopag report a better health-related quality of life than those who switched to romiplostim. this study utilized a hybrid design of retrospective chart review study and cross-sectional patient survey. a customized patient case report form (crf) will be used to retrospectively collect clinical data from patient medical charts where the primary cohorts consist of patients who have switched from other itp medication to eltrombopag or romiplostim. a cross-sectional survey will be employed to collect patient reported outcomes (pro) data, including health-related quality of life and treatment satisfaction, using a compository questionnaire. analyses of cross-sectional survey data and retrospective medical chart review data in patients who switch to either eltrombopag or romiplostim from their prior primary therapy will be conducted.


Eligibility criteria:
inclusion criteria * adults 18 years and older diagnosed with chronic itp * switched to eltrombopag or romiplostim a minimum of 4 weeks prior to index date * received corticosteroids, rituximab, or one tpo-receptor agonist as prior primary therapy before switching to eltrombopag or romiplostim * medical history must be available from chronic itp diagnosis through to most recent office visit * patients who complete the self-administered questionnaire were the same patients whose medical charts were reviewed exclusion criteria * age less than 18 years old

Keywords: treatment satisfaction romiplostim eltrombopag chronic immune thrombocytopenic pupura
the phase ii study of bardoxolone methyl in patients with chronic kidney disease and type 2 diabetes; tsubaki study

Conditions: Chronic Kidney Disease; Type 2 Diabetes

Summary: the purpose of this study is to assess the safety and efficacy of rta 402 in chronic kidney disease (ckd) patients with type 2 diabetes in a double-blind, placebo-controlled study when this compound is administered once daily for 16 weeks in an intrapatient dose escalation design.


Eligibility criteria:
inclusion criteria: * ckd patients with type 2 diabetes mellitus * patients whose estimated gfr levels are eligible for this study * patients being treated with stable dose of angiotensin converting enzyme (ace) inhibitors and/or angiotensin ii receptor blocker (arb) etc. exclusion criteria: * patients with type 1 diabetes mellitus * patients with known non-diabetic renal disease * patients with a history of renal transplantation * patients with mean systolic blood pressure \> 160 mmhg or diastolic blood pressure \> 90 mmhg * patients with hemoglobin a1c \> 10% * patients with cardiovascular disease specified in the study protocol etc.

Keywords: diabetes mellitus diabetes mellitus, type 2 diabetic nephropathies kidney diseases renal insufficiency, chronic diabetes complications endocrine system diseases glucose metabolism disorders metabolic diseases renal insufficiency urologic diseases bardoxolone methyl
machine learning based ct angiography derived ffr: a multi-center, registry

Conditions: Coronary Heart Disease; Coronary Artery Disease

Summary: demonstrate in a large multicenter population the diagnostic performance of a pre-commercial on-site, local, ct angiography derived ffr algorithm in comparison to invasive ffr.

to retrospectively evaluate the diagnostic accuracy of ffrct, in patients with known or suspected cad. the investigators propose to do technical assessment of the software and evaluate how different parameters effect the outcome. validate the fftct outcome by comparing the ffrct values with invasive ffr values from retrospective patient data. to analyze the potential of ffrct on decision making and prognosis.

Eligibility criteria:
inclusion criteria: * know or suspect coronary artery disease followed within 6 months by an invasive ffr measurement. exclusion criteria: * cardiac event between coronary ct angiography and the invasive ffr procedure, noninterpretable coronary ct angiography image quality, or incomplete coronary ct angiography coverage.
empowering immigrants in the greater boston area to connect to hbv care

Conditions: Hepatitis

Summary: this study will attempt to provide information / linkage to hbv care for persons at risk in the greater boston area.

specific aims 1. provide hbv education at community sites where immigrants at risk for hbv could be informed of the risks related to hbv, in a culturally and linguistically sensitive manner. 1. chelsea, charlestown, and revere mgh community health centers: posters, pamphlets, and telephone line to provide hbv education 2. senegalese community center: community meeting, posters, and pamphlets 3. african students' association, suffolk university: community meeting, posters, and pamphlets 4. revere cambodian community centers: community meeting, posters, and pamphlets 2. provide at-risk persons with the tools to develop an hbv diagnosis plan with his / her provider. 1. provide counseling on the significance of different testing results prior to testing 2. connect to testing, and appropriate post-test follow-up appointments 3. provide an education hub for patients and providers to return to with questions regarding: test interpretation, available treatments for those who test positive, and screening for hepatocellular carcinoma in those who are infected. 1. provide copy of an easy to understand us hbv treatment algorithm in native languages 2. provide information related to genotype-specific risks for hcc (increased with gt c).

Eligibility criteria:
inclusion criteria: all persons interested in hearing more information about hbv - exclusion criteria: children -
estradiol suppression for the treatment of metastatic breast cancer in premenopausal women

Conditions: Breast Cancer

Summary: to evaluate the antitumor activity, toxicity, and effectiveness of the combination of goserelin (zoladex) and anastrozole (arimidex) in the treatment of premenopausal women with hormone receptor positive metastatic carcinoma of the breast.

pre-menopausal women with estrogen and/or progesterone receptor positive, metastatic or recurrent breast cancer were enrolled and treated with goserelin (zoladex) monthly and began anastrozole (arimidex) daily for 21 days following the first injection of goserelin. participants continued on treatment until disease progression or unacceptable toxicity.

Eligibility criteria:
inclusion criteria * histologically-confirmed, bi-dimensionally measurable, recurrent or metastatic carcinoma of the breast that is progressive * premenopausal, defined as any of: 1. last menstrual period within 3 months, or 2. post-hysterectomy without bilateral oophorectomy and with follicle-stimulating hormone (fsh) in the premenopausal range, or, 3. if tamoxifen administered within the past 3 months, plasma estradiol must be in the premenopausal range * either positive estrogen and/or progesterone receptor determination by immunohistochemistry (ihc) or competitive binding assay on metastatic disease, or if not performed on their metastatic disease a positive result on their primary breast cancer specimen. * eastern cooperative oncology group (ecog) performance status of 0, 1, or 2 * granulocytes \> 1500/mm\^3 * platelets \> 100,000/mm\^3 * serum glutamic oxaloacetic transaminase (sgot) \< 2.5 x upper limit of normal * total bilirubin \< 1.5 mg/dl * may have received irradiation to bony sites of disease for pain control or for prevention of fracture. the irradiated site(s) will not be evaluable for disease response. * must be using effective contraception or not be of childbearing potential * signed written informed consent inclusion criteria * active, unresolved infection * active malignancy other than breast cancer, in situ carcinoma of the cervix, or non-melanomatous skin cancers in the past 5 years * prior treatment with an aromatase inhibitor or inactivator * prior treatment with an luteinizing hormone-releasing hormone (lh/rh) agonist/antagonist * adjuvant chemotherapy within 6 months of study entry. * received chemotherapy or hormonal therapy in the 3 weeks prior to enrollment * central nervous system metastasis * lymphangitic pulmonary metastasis * pregnant or lactating
effectiveness of an interdisciplinary, nurse-coordinated atrial fibrillation expert program for primary care patients

Conditions: Atrial Fibrillation

Summary: the purpose of this study is to assess the effectiveness of a newly developed interdisciplinary nurse-coordinated af expert program for primary care patients. therefore a prospective, pragmatic clustered randomized controlled trial will be performed in general practices.


Eligibility criteria:
inclusion criteria: * every newly diagnosed af patient. * every af patient who is not seen by a cardiologist or electrophysiologist in the past 2 years before inclusion. * af must be confirmed on electrocardiogram. * capable of providing written informed consent. * dutch speaking and verbally testable, without cognitive impairment. exclusion criteria: * af patients who once received an arrhythmologic consult about af prior to the start of the study. * af patients who have a systematic follow-up at a cardiologist prior to the start of the study. * terminally ill af patients * participation in another clinical trial

Keywords: nurse expert program primary care implementation interdisciplinary effectiveness disease management system